Back to Index
Anil Tulpule, MD
Associate Professor of Clinical Medicine
NOR 3458 Health Sciences Campus Los Angeles
+1 323 865 3927


Dr. Tulpule began his medical education and career in his native India before coming to Southern California on a fellowship in medical oncology at the Keck School of Medicine. After completion of his first USC fellowship, Dr. Tulpule was granted an additional fellowship in the Department of Hematology where he is currently holds an assistant professor appointment. Dr. Tulpule remains active in AIDS research, including a ten year affiliation with the government sponsored AIDS-Related Malignancy Working Group at the National Cancer Institute.

He has received over fifteen research grants on a number of hematology related subjects and his work has been published in many noted medical journals. Dr. Tulpule is a member of the LAC+USC Medical Center’s Internal Review Board and has a role in determining the ethical implications of the center’s research studies. His dedication to ethical practices also includes a membership of USC Norris Comprehensive Cancer Center’s Patient’s Rights Committee.


Xie Y, Bulbul MA, Ji L, Inouye CM, Groshen SG, Tulpule A, O'Malley DP, Wang E, Siddiqi IN. p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression: A Single Institutional Clinicopathologic Study. Am J Clin Pathol. 2014 Apr; 141(4):593-604. View in: PubMed

Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 1; 31(1):58-64. View in: PubMed

Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010 Dec; 11(12):1149-59. View in: PubMed

Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010 Aug 15; 116(16):3969-77. View in: PubMed

Liu R, Gong M, Li X, Zhou Y, Gao W, Tulpule A, Chaudhary PM, Jung J, Gill PS. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood. 2010 Jul 15; 116(2):297-305. View in: PubMed

Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill PS. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood. 2010 Jan 28; 115(4):887-95. View in: PubMed

Masiello D, Tulpule A. Bendamustine therapy in chronic lymphocytic leukemia. Expert Opin Pharmacother. 2009 Jul; 10(10):1687-98. View in: PubMed

Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008 Sep 20; 26(27):4473-9. View in: PubMed

Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006 Oct 15; 107(8):1909-17. View in: PubMed

Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, Dharmapala D, Gee C, Boswell WD, Nathwani BN, Welles L, Levine AM. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2006 Jul; 7(1):59-64. View in: PubMed

Levine AM, Tulpule A, Quinn DI, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. View in: PubMed

Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005 Nov 20; 23(33):8477-82. View in: PubMed

Tulpule A. Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol. 2005 Sep; 17(5):466-8. View in: PubMed

Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005 Jul 1; 23(19):4430-8. View in: PubMed

Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10; 23(5):990-8. View in: PubMed

Masood R, Xia G, Smith DL, Scalia P, Still JG, Tulpule A, Gill PS. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood. 2005 Feb 1; 105(3):1310-8. View in: PubMed

Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, Nathwani BN, Welles L. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004 Jul 1; 22(13):2662-70. View in: PubMed

Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM. Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Invest New Drugs. 2004 Jan; 22(1):63-8. View in: PubMed

Tulpule A, Groopman J, Saville MW, Harrington W, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002 Jul 1; 95(1):147-54. View in: PubMed

Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer. 2002 Mar 1; 94(5):1500-6. View in: PubMed

Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill PS, Levine AM. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res. 2002 Feb; 26(2):121-7. View in: PubMed

Powered bySC CTSI